<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02044419</url>
  </required_header>
  <id_info>
    <org_study_id>AEGR-733-032</org_study_id>
    <nct_id>NCT02044419</nct_id>
  </id_info>
  <brief_title>A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs Sprinkled</brief_title>
  <official_title>A Phase 1, Open-label, Randomised, Crossover Study to Determine the Comparative Bioavailability of 20 mg Lomitapide Where the Contents Have Been Opened and Sprinkled in Applesauce or Mashed Banana (&quot;Sprinkled Contents&quot;) to a Single Oral Capsule Dose of 20 mg Lomitapide (&quot;Intact Capsule&quot;) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aegerion Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aegerion Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the relative bioavailability of lomitapide when administered by sprinkling the
      contents of a 20 mg capsule of lomitapide in applesauce or in mashed banana to a single oral
      intact capsule dose of 20 mg lomitapide in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2013</start_date>
  <completion_date type="Actual">December 23, 2013</completion_date>
  <primary_completion_date type="Actual">December 23, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose</time_frame>
    <description>Area under the concentration-time curve from hour 0 to the last measurable concentration of lomitapide and its metabolites (M1&amp; M3).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose</time_frame>
    <description>Maximum observed concentration of lomitapide and its metabolites (M1&amp; M3).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose</time_frame>
    <description>Time to reach maximum plasma concentration of lomitapide and its metabolites (M1&amp; M3).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose</time_frame>
    <description>Terminal elimination half-life of lomitapide and its metabolites (M1&amp; M3).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose</time_frame>
    <description>Area under the plasma concentration vs time curve from zero to infinity of lomitapide and its metabolites (M1&amp; M3).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>λz</measure>
    <time_frame>predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose</time_frame>
    <description>Elimination rate constant estimated from individual linear regression of the terminal part of the log concentration vs time curve of lomitapide and its metabolites (M1&amp; M3).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>lomitapide sprinkled in applesauce</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contents of single 20 mg capsule of lomitapide sprinkled in applesauce</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lomitapide sprinkled in mashed banana</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lomitapide (intact)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intact capsule of 20 mg lomitapide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lomitapide</intervention_name>
    <arm_group_label>lomitapide sprinkled in applesauce</arm_group_label>
    <arm_group_label>lomitapide sprinkled in mashed banana</arm_group_label>
    <arm_group_label>lomitapide (intact)</arm_group_label>
    <other_name>Juxtapid</other_name>
    <other_name>Lojuxta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is a non-smoking healthy male or female, aged between 18 and 40 years of age.

          2. Subject has a BMI of 18.5 - 25 kg/m2.

          3. Subject has total body weight between &gt; 50 kg to ≤ 100 kg.

          4. Subjects must agree to use acceptable methods of contraception.

          5. All females, regardless of childbearing potential, must have a negative serum beta
             human chorionic gonadotropin pregnancy test at Screening and on admission.

          6. In good health, determined by no clinically significant or relevant abnormalities
             identified by a detailed medical history &amp; full physical examination.

          7. No known history of hypersensitivity or previous intolerance to lomitapide,
             applesauce, and/or banana.

          8. Subjects must be capable of understanding and complying with the requirements of the
             protocol and must have signed the informed consent form prior to undergoing any
             study-related procedures.

        Exclusion Criteria:

          1. Subject has a clinically significant disease or any condition or disease that might
             affect drug absorption, distribution or excretion.

          2. History of stomach or intestinal surgery or resection that would potentially alter
             absorption and/or excretion of orally administered drugs.

          3. Any clinically significant abnormal laboratory, vital signs or other safety findings
             as determined by medical history, physical examination or other evaluations.

          4. History of significant hypersensitivity, intolerance, or allergy to any drug compound,
             food, or other substance, unless approved by the Investigator;

          5. Electrocardiogram (ECG) abnormalities in the standard 12-lead ECG (at screening) such
             as a QTcF interval of &gt;450 msec, a history of a prolonged QTc interval or Brugada
             syndrome.

          6. History or current evidence of any clinically relevant cardiovascular, pulmonary,
             hepatic, renal, gastrointestinal, haematological, endocrinological, allergic,
             dermatological, metabolic, neurological, psychiatric or other disease.

          7. History or laboratory evidence of Gilbert's syndrome.

          8. Positive results in any of the serology tests for Hepatitis B Surface Antigen (HbsAg),
             anti-Hepatitis core antibody (anti-HBc Ig G [and anti-HBc IgM if IgG is positive],
             Hepatitis C antibodies (anti-HCV), and HIV 1 and 2 antibodies, (anti-HIV 1/2).

          9. Use of any drugs of abuse within 6 months prior to admission.

         10. Confirmed positive results from urine drug screen (amphetamines, benzodiazepines,
             cocaine, cannabinoids, opiates, barbiturates and methadone) or from the alcohol breath
             test at screening and on admission (Day -1).

         11. History or clinical evidence of alcohol or drug abuse within one year prior to
             admission.

         12. Mentally handicapped.

         13. Participation in a drug trial within 90 days prior to first drug administration.

         14. Use of any prescription medication within 2 weeks prior to admission (Day -1), with
             the exception of the oral contraceptive pill.

         15. Use of any substance inducing or inhibiting CYP3A4 enzymes within 30 days prior to
             admission (Day -1).

         16. Use of any over-the-counter (OTC) medication (including vitamins, minerals, and
             phytotherapeutic/herbal/plant-derived preparations) within 7 days prior to admission
             (Day -1), unless deemed acceptable by the Investigator and Sponsor.

         17. Use of alcohol-, grapefruit-, starfruit-, or caffeine-containing foods or beverages
             within 72 hours prior to admission and through Study Completion.

         18. Donation of more than 500 mL of blood within 90 days prior to drug administration.

         19. Receipt of blood products within 2 months prior to admission.

         20. Poor peripheral venous access.

         21. Use of any tobacco- or nicotine-containing products within 6 months prior to admission
             (Day -1).

         22. Any acute or chronic condition, scheduled hospitalisation (inclusive of elective
             surgery during study), or scheduled travel prior to completion of all study
             procedures.

         23. Any circumstances or conditions, which, in the opinion of the PI, may affect full
             participation in the trial or compliance with the protocol.

         24. Legal incapacity or limited legal capacity at screening.

         25. Subjects who are vegetarians, vegans or have any dietary restrictions conflicting with
             the study standardised menus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Sumeray, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Aegerion Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrike Lorch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Richmond Phamacology, LTD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Richmond Pharmacology Ltd</name>
      <address>
        <city>Croydon</city>
        <state>Surrey</state>
        <zip>CR7 7YE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2013</study_first_submitted>
  <study_first_submitted_qc>January 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2014</study_first_posted>
  <results_first_submitted>June 23, 2015</results_first_submitted>
  <results_first_submitted_qc>February 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 13, 2018</results_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Comparative</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>lomitapide</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Applesauce, Mashed Banana, Intact Capsule (ABC)</title>
          <description>First Intervention: Contents of single 20 mg capsule of lomitapide sprinkled in applesauce Second Intervention: Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana Third Intervention: Intact capsule of 20 mg lomitapide</description>
        </group>
        <group group_id="P2">
          <title>Mashed Banana, Intact Capsule, Applesauce (BCA)</title>
          <description>First Intervention: Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana Second Intervention: Intact capsule of 20 mg lomitapide Third Intervention: Contents of single 20 mg capsule of lomitapide sprinkled in applesauce</description>
        </group>
        <group group_id="P3">
          <title>Intact Capsule, Applesauce, Mashed Banana (CAB)</title>
          <description>First Intervention: Contents of single 20 mg capsule of lomitapide sprinkled in applesauce Second Intervention: Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana Third Intervention: Intact capsule of 20 mg lomitapide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Applesauce, Mashed Banana, Intact Capsule (ABC)</title>
          <description>Contents of single 20 mg capsule of lomitapide sprinkled in applesauce, mashed banana
Capsule taken intact
lomitapide</description>
        </group>
        <group group_id="B2">
          <title>Mashed Banana, Intact Capsule, Applesauce (BCA)</title>
          <description>Contents of single 20 mg capsule of lomitapide sprinkled in applesauce&amp; mashed banana
Capsule taken intact
lomitapide</description>
        </group>
        <group group_id="B3">
          <title>Intact Capsule, Applesauce, Mashed Banana (CAB)</title>
          <description>Contents of single 20 mg capsule of lomitapide sprinkled in applesauce&amp; mashed banana
Capsule taken intact
lomitapide</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.45" spread="5.837"/>
                    <measurement group_id="B2" value="25.90" spread="5.131"/>
                    <measurement group_id="B3" value="27.91" spread="3.27"/>
                    <measurement group_id="B4" value="27.42" spread="4.746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t</title>
        <description>Area under the concentration-time curve from hour 0 to the last measurable concentration of lomitapide and its metabolites (M1&amp; M3).</description>
        <time_frame>predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set included all subjects who received at least one single dose of lomitapide and who had evaluable PK data</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Sprinkled in Applesauce (Treatment A)</title>
            <description>Contents of single 20 mg capsule of lomitapide sprinkled in applesauce</description>
          </group>
          <group group_id="O2">
            <title>Lomitapide Sprinkled in Mashed Banana (Treatment B)</title>
            <description>Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana</description>
          </group>
          <group group_id="O3">
            <title>Intact Capsule of 20 mg Lomitapide (Treatment C)</title>
            <description>Intact capsule of 20 mg lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t</title>
          <description>Area under the concentration-time curve from hour 0 to the last measurable concentration of lomitapide and its metabolites (M1&amp; M3).</description>
          <population>Pharmacokinetic Analysis Set included all subjects who received at least one single dose of lomitapide and who had evaluable PK data</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lomitapide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" spread="15.2"/>
                    <measurement group_id="O2" value="40.2" spread="13.4"/>
                    <measurement group_id="O3" value="43.6" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4" spread="20.2"/>
                    <measurement group_id="O2" value="72.9" spread="23.1"/>
                    <measurement group_id="O3" value="75.2" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="443" spread="308"/>
                    <measurement group_id="O2" value="450" spread="292"/>
                    <measurement group_id="O3" value="460" spread="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximum observed concentration of lomitapide and its metabolites (M1&amp; M3).</description>
        <time_frame>predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set included all subjects who received at least one single dose of lomitapide and who had evaluable PK data</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Sprinkled in Applesauce (Treatment A)</title>
            <description>Contents of single 20 mg capsule of lomitapide sprinkled in applesauce</description>
          </group>
          <group group_id="O2">
            <title>Lomitapide Sprinkled in Mashed Banana (Treatment B)</title>
            <description>Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana</description>
          </group>
          <group group_id="O3">
            <title>Intact Capsule of 20 mg Lomitapide (Treatment C)</title>
            <description>Intact capsule of 20 mg lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum observed concentration of lomitapide and its metabolites (M1&amp; M3).</description>
          <population>Pharmacokinetic Analysis Set included all subjects who received at least one single dose of lomitapide and who had evaluable PK data</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lomitapide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.986" spread="0.536"/>
                    <measurement group_id="O2" value="1.03" spread="0.463"/>
                    <measurement group_id="O3" value="1.13" spread="0.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" spread="0.748"/>
                    <measurement group_id="O2" value="2.65" spread="0.813"/>
                    <measurement group_id="O3" value="2.74" spread="0.796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" spread="15.6"/>
                    <measurement group_id="O2" value="31.0" spread="13.3"/>
                    <measurement group_id="O3" value="28.6" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax</title>
        <description>Time to reach maximum plasma concentration of lomitapide and its metabolites (M1&amp; M3).</description>
        <time_frame>predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set included all subjects who received at least one single dose of lomitapide and who had evaluable PK data</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Sprinkled in Applesauce (Treatment A)</title>
            <description>Contents of single 20 mg capsule of lomitapide sprinkled in applesauce</description>
          </group>
          <group group_id="O2">
            <title>Lomitapide Sprinkled in Mashed Banana (Treatment B)</title>
            <description>Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana</description>
          </group>
          <group group_id="O3">
            <title>Intact Capsule of 20 mg Lomitapide (Treatment C)</title>
            <description>Intact capsule of 20 mg lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time to reach maximum plasma concentration of lomitapide and its metabolites (M1&amp; M3).</description>
          <population>Pharmacokinetic Analysis Set included all subjects who received at least one single dose of lomitapide and who had evaluable PK data</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lomitapide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="1.00" upper_limit="12.0"/>
                    <measurement group_id="O2" value="5.00" lower_limit="1.00" upper_limit="12.0"/>
                    <measurement group_id="O3" value="5.00" lower_limit="2.00" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="5.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="5.00" lower_limit="3.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="3.00" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2</title>
        <description>Terminal elimination half-life of lomitapide and its metabolites (M1&amp; M3).</description>
        <time_frame>predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set included all subjects who received at least one single dose of lomitapide and who had evaluable PK data</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Sprinkled in Applesauce (Treatment A)</title>
            <description>Contents of single 20 mg capsule of lomitapide sprinkled in applesauce</description>
          </group>
          <group group_id="O2">
            <title>Lomitapide Sprinkled in Mashed Banana (Treatment B)</title>
            <description>Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana</description>
          </group>
          <group group_id="O3">
            <title>Intact Capsule of 20 mg Lomitapide (Treatment C)</title>
            <description>Intact capsule of 20 mg lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2</title>
          <description>Terminal elimination half-life of lomitapide and its metabolites (M1&amp; M3).</description>
          <population>Pharmacokinetic Analysis Set included all subjects who received at least one single dose of lomitapide and who had evaluable PK data</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lomitapide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" spread="13.3"/>
                    <measurement group_id="O2" value="47.7" spread="12.2"/>
                    <measurement group_id="O3" value="48.8" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" spread="7.56"/>
                    <measurement group_id="O2" value="37.0" spread="6.78"/>
                    <measurement group_id="O3" value="39.1" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0" spread="13.1"/>
                    <measurement group_id="O2" value="45.7" spread="11.5"/>
                    <measurement group_id="O3" value="44.0" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞</title>
        <description>Area under the plasma concentration vs time curve from zero to infinity of lomitapide and its metabolites (M1&amp; M3).</description>
        <time_frame>predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set included all subjects who received at least one single dose of lomitapide and who had evaluable PK data</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Sprinkled in Applesauce (Treatment A)</title>
            <description>Contents of single 20 mg capsule of lomitapide sprinkled in applesauce</description>
          </group>
          <group group_id="O2">
            <title>Lomitapide Sprinkled in Mashed Banana (Treatment B)</title>
            <description>Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana</description>
          </group>
          <group group_id="O3">
            <title>Intact Capsule of 20 mg Lomitapide (Treatment C)</title>
            <description>Intact capsule of 20 mg lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞</title>
          <description>Area under the plasma concentration vs time curve from zero to infinity of lomitapide and its metabolites (M1&amp; M3).</description>
          <population>Pharmacokinetic Analysis Set included all subjects who received at least one single dose of lomitapide and who had evaluable PK data</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lomitapide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" spread="17.7"/>
                    <measurement group_id="O2" value="43.8" spread="15.3"/>
                    <measurement group_id="O3" value="47.7" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.8" spread="20.8"/>
                    <measurement group_id="O2" value="75.2" spread="23.7"/>
                    <measurement group_id="O3" value="77.8" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="457" spread="317"/>
                    <measurement group_id="O2" value="464" spread="300"/>
                    <measurement group_id="O3" value="474" spread="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>λz</title>
        <description>Elimination rate constant estimated from individual linear regression of the terminal part of the log concentration vs time curve of lomitapide and its metabolites (M1&amp; M3).</description>
        <time_frame>predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set included all subjects who received at least one single dose of lomitapide and who had evaluable PK data</population>
        <group_list>
          <group group_id="O1">
            <title>Lomitapide Sprinkled in Applesauce (Treatment A)</title>
            <description>Contents of single 20 mg capsule of lomitapide sprinkled in applesauce</description>
          </group>
          <group group_id="O2">
            <title>Lomitapide Sprinkled in Mashed Banana (Treatment B)</title>
            <description>Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana</description>
          </group>
          <group group_id="O3">
            <title>Intact Capsule of 20 mg Lomitapide (Treatment C)</title>
            <description>Intact capsule of 20 mg lomitapide</description>
          </group>
        </group_list>
        <measure>
          <title>λz</title>
          <description>Elimination rate constant estimated from individual linear regression of the terminal part of the log concentration vs time curve of lomitapide and its metabolites (M1&amp; M3).</description>
          <population>Pharmacokinetic Analysis Set included all subjects who received at least one single dose of lomitapide and who had evaluable PK data</population>
          <units>1/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lomitapide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0140" spread="0.00341"/>
                    <measurement group_id="O2" value="0.0153" spread="0.00343"/>
                    <measurement group_id="O3" value="0.0149" spread="0.00320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0185" spread="0.00344"/>
                    <measurement group_id="O2" value="0.0195" spread="0.00457"/>
                    <measurement group_id="O3" value="0.0182" spread="0.00309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0161" spread="0.00408"/>
                    <measurement group_id="O2" value="0.0162" spread="0.00428"/>
                    <measurement group_id="O3" value="0.0167" spread="0.00405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lomitapide Sprinkled in Applesauce (Treatment A)</title>
          <description>Contents of single 20 mg capsule of lomitapide sprinkled in applesauce</description>
        </group>
        <group group_id="E2">
          <title>Lomitapide Sprinkled in Mashed Banana (Treatment B)</title>
          <description>Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana</description>
        </group>
        <group group_id="E3">
          <title>Intact Capsule of 20 mg Lomitapide (Treatment C)</title>
          <description>Intact capsule of 20 mg lomitapide</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>Constipation Vomitting</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Described in contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alison Long, MD - VP Clinical</name_or_title>
      <organization>Aegerion Pharmaceuticals, Inc.</organization>
      <phone>857-242-5142</phone>
      <email>alison.long@aegerion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

